

Instructions to Authors 2014

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:

(a) *First page* including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "review", "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) *Abstract* not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) *Introduction*; (d) *Materials and Methods/Patients and Methods*; (e) *Results*; (f) *Discussion*; (g) *Acknowledgements*; (h) *References*. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, at the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Colour plates are charged.

Tables. Tables should be typed double-spaced on a separate page, numbered with Roman numerals and should include a short title.

References. Authors must assume responsibility for the accuracy of the references used. Citations for the reference sections of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216, 1981. 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones* (O' Malley BW, Chamnes GC (eds.). New York, Plenum Publ Corp., pp 113-136, 1973.

Nomenclature and Abbreviations. Nomenclature should follow that given in "Chemical Abstracts", "Index Medicus", "Merck Index", "IUPAC –IUB", "Bergey's Manual of Determinative Bacteriology", The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (<http://www.gene.ucl.ac.uk/>). Approved mouse nomenclature may be obtained from <http://www.informatics.jax.org/>. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by "ISRCTN"). Please note that there is no space between the prefix "ISRCTN" and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

Ethical Policies and Standards. ANTICANCER RESEARCH agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your article twice.):

1. To submit your article online please visit: IIAR-Submissions (<http://www.iiar-anticancer.org/submissions/login.php>)
2. You can send your article via e-mail to journals@iiar-anticancer.org. Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies to the following address:

John G. Delinasios
 International Institute of Anticancer Research (IIAR)
 Editorial Office of ANTICANCER RESEARCH,
 IN VIVO, CANCER GENOMICS and PROTEOMICS.
 1st km Kapandritiou-Kalamou Road
 P.O. Box 22, GR-19014 Kapandriti, Attiki
 GREECE

Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Requests should be addressed to the Editorial Office.

Copyright© 2014 - International Institute of Anticancer Research (J.G. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.

in vivo

- International Journal of Experimental and Clinical Pathophysiology and Drug Research
- Published bimonthly by the International Institute of Anticancer Research
- Available online with Stanford University HighWire Press

ISSN (print): 0258-851X; ISSN (online): 1791-7549

General Policy

- IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the framework of comparative physiology and pathology. The special focus of the journal is the publication of works on: (a) experimental development and the application of new diagnostic procedures; (b) pharmacological and toxicological evaluation of new drugs and drug combinations; (c) development and characterization of models for biomedical research.
- One of the principal aims of IN VIVO is to provide for the prompt publication of accepted articles, generally within 1-2 months from final acceptance.
- IN VIVO supports: (a) the aims and the research program of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (IIAR) (Kapandriti, Attiki, Greece) and (b) the organization of the INTERNATIONAL CONFERENCES OF ANTICANCER RESEARCH.

Editorial Office

International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece. Tel and Fax: +30-22950-53389; e-mail: journals@iiar-anticancer.org

For more information about IN VIVO, IIAR and the conferences please visit the IIAR websites: www.iiar-anticancer.org and www.iv.iiarjournals.org

Selection of Recent Articles

Cryopreservation of Viable Human Lung Tissue for Versatile Post-thaw Analyses and Culture. J.E. BAATZ, D.A. NEWTON, E.C. RIEMER, C.E. DENLINGER, E.E. JONES, R.R. DRAKE, D.D. SPYROPOULOS (*Charleston, SC, USA*)

Establishment and Characterization of New Orthotopic and Metastatic Neuroblastoma Models. E. DAUDIGEOS-DUBUS, L. LE DRET, V. ROUFFIAC, O. BAWA, I. LEGUERNEY, P. OPOLON, G. VASSAL, B. GEOERGER (*Orsay; Villejuif, France*)

Comparative Study of Prescribing Patterns of Tigecycline for Trial-Patients versus Non-Trial-Patients. J.J. HORSCHT, J.B. ZIMMERMANN, M.A. WEIGAND, T. BRUCKNER, E.O. MARTIN, T. HOPPE-TICHY, S. SWOBODA (*Heidelberg; Gießen, Germany*)

Effects of the Bifunctional Sulfoxide MMS350, A Radiation Mitigator, on Hematopoiesis in Long-Term Bone Marrow Cultures and on Radioresistance of Marrow Stromal Cell Lines. A. SHINDE, M.W. EPPERLY, S. CAO, D. FRANICOLA, D. SHIELDS, H. WANG, P. WIPF, M.M. SPRACHMAN, J.S. GREENBERGER (*Pittsburgh, PA, USA*)

The Need for Surgery in Acute Abdominal Pain: A Randomized Study of Abdominal Computed Tomography. P. JUVONEN, T. LEHTIMÄKI, M. ESKELINEN, I. ILVES, R. VANNINEN, P. MIETTINEN, H. PAAJANEN (*Kuopio, Finland*)

Inhibitory Action of Levocetirizine on the Production of Eosinophil Chemoattractants RANTES and Eotaxin In Vitro and In Vivo. A. KANEI, K. ASANO, K.-I. KANAI, A. FURUTA, K. SASAKI, H. SUZAKI (*Tokyo; Yokohama, Japan*)

Poor Memory Performance in Aged Cynomolgus Monkeys with Hippocampal Atrophy, Depletion of Amyloid Beta 1-42 and Accumulation of Tau Proteins in Cerebrospinal Fluid. H.S. DARUSMAN, J. PANDELAKI, R. MULYADI, D. SAJUTHI, I.A. PUTRI, O.H. KALLIOKOSKI, J. CALL, K.S.P. ABELSON, S.J. SCHAPIRO, A. GJEDDE, J. HAU (*Copenhagen; Aarhus, Denmark; Jakarta; Bogor, Indonesia; Leipzig, Germany; Bastrop, TX; Baltimore, MD, USA; Montreal, QC, Canada*)

Effects of Interactions between Progesterone and Prostaglandin on Uterine Contractility in Perfused Swine Uterus Model. J. KÜNZEL, K. GEISLER, T. MALTARIS, A. MÜLLER, I. HOFFMANN, H. SCHNEIDER, M.W. BECKMANN, R. DITTRICH, P.G. OPPELT (*Erlangen, Germany*)

Esophageal Radioprotection in Thoracic Irradiated Mice with Transgenic Lung Tumors by Swallowed JP4-039/F15. M.W. EPPERLY, J.P. GOFF, D. FRANICOLA, H. WANG, P. WIPF, S. LI, J.S. GREENBERGER (*Pittsburgh, PA, USA*)

Malignant Ascites in Ovarian Cancer and the Role of Targeted Therapeutics. E. SMOLLE, V. TAUCHER, J. HAYBAECK (*Graz, Austria*)

Increased DNA Integrity in Colorectal Cancer. G. LESZINSKI, J. LEHNER, U. GEZER, S. HOLDENRIEDER (*Munich; Bonn, Germany; Istanbul, Turkey*)

Circulating Human Fractalkine is Decreased Post-operatively After Orthopedic and Coronary Bypass Surgery. T. EKERFELDT, J. HELMERSSON-KARLQVIST, T. GORDH, A. LARSSON (*Uppsala, Sweden*)

Circulating miR-18a; A Sensitive Cancer Screening Biomarker in Human Cancer. S. KOMATSU, D. ICHIKAWA, H. TAKESHITA, R. MORIMURA, S. HIRAJIMA, M. TSUJIURA, T. KAWAGUCHI, M. MIYAMAE, H. NAGATA, H. KONISHI, A. SHIOZAKI, E. OTSUJI (*Kyoto, Japan*)

Antioxidant Effects of Lipophilic Tea Polyphenols on Diethylnitrosamine/Phenobarbital-induced Hepatocarcinogenesis in Rats. F. ZHOU, T. SHEN, T. DUAN, Y.-Y. XU, S.C. KHOR, Y.-F. ZHENG, S. HSU, J. DE STEFANO, J. YANG, L.-H. XU, X.-Q. ZHU (*Hangzhou, Zhejiang; Shanghai, PR China; Augusta, GA, USA*)

Anti-inflammatory Effects of Polihexanide and Polyethylene glycol in an In-vitro Study in Chronic Rhinosinusitis. R. BIRK, J. GROSSBAIER, C. ADERHOLD, J. STERN-STRÄTER, K. HÖRMANN, A. SAUTER, J.U. SOMMER (*Heidelberg, Germany*)

Anti-UV Activity of Kampo Medicines and Constituent Plant Extracts: Re-evaluation with Skin Keratinocyte System. T. KATO, S. HINO, N. HORIE, T. SHIMOYAMA, T. KANEKO, K. KUSAMA, H. SAKAGAMI (*Saitama; Tokyo, Japan*)

FREE SPECIMEN COPIES OF IN VIVO ARE AVAILABLE ON REQUEST

| | |
|---|------|
| Evaluation of Radioprotective Effect of Pilocarpine Ingestion on Salivary Glands. M.J. PIMENTEL, M.M. BATISTA FILHO, M. ARAÚJO, D.Q. GOMES, L.J. DA COSTA (<i>Piracicaba, SP; Joao Pessoa; Campina Grande, PB, Brazil</i>) | 1993 |
| Effect of Co-administration of Ketoconazole, a Strong CYP3A Inhibitor, on the Pharmacokinetics, Safety and Tolerability of Navitoclax, a First-in-class Oral Bcl-2 Family Inhibitor, in Cancer Patients. A.H. SALEM, J. YANG, A. GRAHAM, A. PATNAIK, K. HOLEN, R. PRADHAN, H. XIONG (<i>North Chicago, IL; San Antonio, TX; Cheshire, CT, USA; Cairo, Egypt</i>) | 2001 |
| Impact of Combination Chemotherapy with Itraconazole on Survival for Patients with Recurrent or Persistent Ovarian Clear Cell Carcinoma. H. TSUBAMOTO, T. SONODA, M. YAMASAKI, K. INOUE (<i>Nishinomiya; Kobe, Hyogo, Japan</i>) | 2007 |
| Comparison of Common Terminology Criteria for Adverse Events v3.0 and Radiation Therapy Oncology Group Toxicity Score System After High-dose-rate Interstitial Brachytherapy as Monotherapy for Prostate Cancer. K. YOSHIDA, H. YAMAZAKI, S. NAKAMARA, K. MASUI, T. KOTSUMA, H. AKIYAMA, E. TANAKA, Y. YOSHIOKA (<i>Takatsuki; Osaka; Suita, Osaka; Kyoto, Japan</i>) | 2015 |
| The Role of Prophylactic Hyperthermic Intraperitoneal Chemotherapy in the Management of Serosal Involved Gastric Cancer. E. SALADINO, F. FLERES, C. MAZZEO, V. PRUITI, M. SCOLLICA, M. ROSSITTO, E. CUCINOTTA, A. MACRÌ (<i>Messina, Italy</i>) | 2019 |
| A Pilot Study of Cisplatin and Etoposide With and Without Radiotherapy for Advanced Malignant Thymoma. A. TAMIYA, A. MATSUMURA, T. TSUJI, M. MORIMOTO, K. ASAMI, K. OKISHIO, S. SHIMIZU, H.-E. YOON, S. ATAGI, M. AKIRA, M. KITAICHI, T. KAWAGUCHI (<i>Sakai City, Osaka, Japan</i>) | 2023 |
| Phase I Study of Combination Therapy with Irinotecan, Leucovorin, and Bolus and Continuous-infusion 5-Fluorouracil (FOLFIRI) for Advanced Colorectal Cancer in Japanese Patients. Y. SASAKI, T. HAMAGUCHI, T. ARAI, A. GOTO, T. URA, K. MURO, Y. YAMADA, K. SHIRAO, Y. SHIMADA (<i>Tokyo, Japan</i>) | 2029 |
| Analysis of Adverse Events of Bevacizumab-containing Systemic Chemotherapy for Metastatic Colorectal Cancer in Japan. T. ISOBE, K. UCHINO, C. MAKIYAMA, H. ARIYAMA, S. ARITA, S. TAMURA, M. KOMODA, H. KUSABA, T. SHIRAKAWA, T. ESAKI, K. MITSUGI, S. TAKAISHI, K. AKASHI, E. BABA (<i>Fukuoka, Japan</i>) | 2035 |
| ABSTRACTS OF THE FIFTH INTERNATIONAL SYMPOSIUM ON VITAMIN D ANALOGS IN CANCER PREVENTION AND THERAPY. 2-3 May, 2014, Hotel Krefelder Hof, <i>Krefeld, Germany</i> | 2041 |

| | |
|--|------|
| Novel Ruthenium – Gamma-linolenic Acid Complex Inhibits C6 Rat Glioma Cell Proliferation <i>In Vitro</i> and in the Orthotopic C6 Model <i>In Vivo</i> After Osmotic Pump Infusion. J.A. MIYAKE, M. BENADIBA, G. RIBEIRO, D. DE OLIVEIRA SILVA, A. COLQUHOUN (<i>São Paulo, SP, Brazil</i>) | 1901 |
| Radiosensitizing Effect of Rosmarinic Acid in Metastatic Melanoma B16F10 Cells. M. ALCARAZ, M. ALCARAZ-SAURA, D.G. ACHEL, A. OLIVARES, J.A. LÓPEZ-MORATA, J. CASTILLO (<i>Murcia, Spain; Legon-Accra, Ghana</i>) | 1913 |
| Synthesis and Antitumour Activity of a New Trinuclear Platinum Compound [<i>cis</i> -PtCl(NH ₃) ₂ μ { <i>trans</i> -Pt(3-hydroxypyridine) ₂ H ₂ N(CH ₂) ₅ NH ₂ }] C14 in Human Ovarian Cancer Cells. S.A. HAMAD, P. BEALE, J.Q. YU, F. HUQ (<i>Lidcombe; Sydney, NSW, Australia</i>) | 1923 |
| A Bibenzyl from <i>Dendrobium ellipsophyllum</i> Inhibits Epithelial-to-Mesenchymal Transition and Sensitizes Lung Cancer Cells to Anoikis. C. CHAOTHAM, V. PONGRAKHANANON, B. SRITULARAK, P. CHANVORACHOTE (<i>Bangkok, Thailand</i>) | 1931 |
| <i>Clinical Studies</i> | |
| Pediatric Patients with Refractory Central Nervous System Tumors: Experiences of a Clinical Trial Combining Bevacizumab and Temozolomide. S.A. PIHA-PAUL, S.J. SHIN, T. VATS, N. GUHA-THAKURTA, J. AARON, M. RYTTING, E. KLEINERMAN, R. KURZROCK (<i>Houston, TX; La Jolla, CA, USA</i>) | 1939 |
| An Early-stage, Non-hypervascular HCC Successfully Treated by Superselective, Bland Transarterial Embolization Using 40-μm Microspheres. T. TANAKA, S. MAEDA, H. NISHIOFUKU, T. MASADA, T. SATO, H. ANAI, H. SAKAGUCHI, K. KICHIKAWA (<i>Kashihara; Sango, Nara, Japan</i>) | 1947 |
| Bevacizumab Improves Splenomegaly and Decreases Production of Hyaluronic Acid After L-OHP Based Chemotherapy. Y. ARAKAWA, M. SHIMADA, T. UTSUNOMIYA, S. IMURA, Y. MORINE, T. IKEMOTO, J. HANAOKA, M. KANAMOTO, S. IWAHASHI, Y. SAITO, S. YAMADA, M. ASANOMA, C. TAKASU, Y. BANDO (<i>Tokushima, Japan</i>) | 1953 |
| Full-dose Cisplatin and Oral Vinorelbine Concomitant with Radiotherapy in Unresectable Stage III Non-small Cell Lung Cancer: A Multi-center Phase II Study. Ó. JUAN, A. SÁNCHEZ-HERNÁNDEZ, S. VÁZQUEZ, J. CASAL, J.L. FIRVIDA, F. APARISI, J. MUÑOZ, J. GARCÍA-SÁNCHEZ, R. GIRONÉS, M. LÁZARO, V. GINER (<i>Valencia; Castellón; Lugo; Vigo; Ourense; Alco; Xativa; Sagunto, Spain</i>) | 1959 |
| Multicenter Phase II Study of Second-line Cetuximab plus Folinic Acid/5-Fluorouracil/Irinotecan (FOLFIRI) in <i>KRAS</i> Wild-type Metastatic Colorectal Cancer: The FLIER Study. S. IWAMOTO, S. HAZAMA, T. KATO, Y. MIYAKE, M. FUKUNAGA, C. MATSUDA, H. BANDO, J. SAKAMOTO, K. OBA, H. MISHIMA (<i>Moriguchi; Sakai, Osaka; Ube, Yamaguchi; Nishinomiya; Amagasaki, Hyogo; Kanazawa, Ishikawa; Sapporo, Hokkaido; Kakamigahara, Gifu; Nagakute, Aichi, Japan</i>) | 1967 |
| Phase II Study of Erlotinib for Acquired Resistance to Gefitinib in Patients with Advanced Non-small Cell Lung Cancer. A. HORIIKE, N. YAMAMOTO, H. TANAKA, N. YANAGITANI, K. KUDO, F. OHYANAGI, A. ONO, T. NAITO, H. MURAKAMI, T. HORAI, M. NISHIO (<i>Tokyo; Shizuoka, Japan</i>) | 1975 |
| Oncological Outcomes of Hormonal Therapy with a Gonadotropin-releasing Hormone Agonist Combined with a Steroidal or Non-steroidal Antiandrogen in Patients with Prostate Cancer. T. IGAWA, T. TSURUSAKI, K. NOMATA, M. HAYASHI, M. FURUKAWA, H. SAKAI (<i>Nagasaki; Omura; Sasebo, Japan</i>) | 1983 |
| Multimodal Approach for Cervical Esophageal Carcinoma: Role of Neoadjuvant Chemotherapy. G. SUZUKI, H. YAMAZAKI, E. OGO, T. ABE, H. ETO, K. MURAKI, C. HATTORI, H. UMENO, T. NAKASHIMA, T. TANAKA, S. NAKAMURA, K. YOSHIDA (<i>Kurume, Fukuoka; Kyoto, Kyoto; Takatsuki, Osaka, Japan</i>) | 1989 |

| | |
|---|------|
| Synergistic Cytotoxic Activity of Treosulfan and Gemcitabine in Pancreatic Cancer Cell Lines. E. NITSCH, S. MINA, I. BRAMMER, A. PACE, G. SCHUCH, C. BOKEMEYER, A. ZANDER, N. KRÖGER, F. AYUK (<i>Hamburg, Germany</i>) | 1779 |
| Antiproliferative and Apoptosis-inducing Activity of Nobiletin Against Three Subtypes of Human Breast Cancer Cell Lines. C. CHEN, M. ONO, M. TAKESHIMA, S. NAKANO (<i>Fukuoka, Japan</i>)..... | 1785 |
| COX2 Inhibitor NS398 Reduces HT-29 Cell Invasiveness by Modulating Signaling Pathways Mediated by EGFR and HIF1- α . C. BOCCA, F. BOZZO, A. MIGLIETTA (<i>Turin, Italy</i>) | 1793 |
| Behavior-selective Apoptotic Capacity of 4-(3,4,5-Trimethoxyphenoxy) Benzoic Acid and its Methyl Derivatives on Two Breast Cancer Cell Lines. K.-H. LEE, W.-Y. HO, S.-J. WU, T.-L. CHENG, P.-J. HUANG, C.C.C. WANG, J.-H. HUNG (<i>Tainan; Kaohsiung, Taiwan, ROC; Los Angeles, CA, USA</i>) | 1801 |
| 3,3',4', 5'-Tetramethoxychalcone Inhibits Human Oral Cancer Cell Proliferation and Migration via p53-mediated Mitochondrial-dependent Apoptosis. C.-K. LAI, Y. KOTESWARA RAO, K.-R. CHANG, C.-W. LIN, H.-L. SU, C.-S. CHANG, C.-H. LAI, Y.-M. TZENG (<i>Taichung, Taiwan, ROC</i>) | 1811 |
| Activation of AXL and Antitumor Effects of a Monoclonal Antibody to AXL in Lung Adenocarcinoma. S. IIDA, Y. MIKI, T. SUZUKI, K. MORI, M. SAITO, H. NIKAWA, T. KONDO, H. YAMADA-OKABE, H. SASANO (<i>Sendai, Miyagi; Shizuoka, Japan</i>) | 1821 |
| Induction of Apoptosis by Deinoxanthin in Human Cancer Cells. Y.-J. CHOI, J.-M. HUR, S. LIM, M. JO, D.H. KIM, J.-I. CHOI (<i>Jeongeup; Gwangju, Republic of Korea</i>) | 1829 |
| A Monastrol-derived Compound, LaSOM 63, Inhibits Ecto-5'Nucleotidase/CD73 Activity and Induces Apoptotic Cell Death of Glioma Cell Lines. F. FIGUEIRÓ, F.B. MENDES, P.F. CORBELINI, F. JANARELLI, E.H. JANDREY, D. RUSSOWSKY, V.L. EIFLER-LIMA, A.M. BATTASTINI (<i>Porto Alegre, RS, Brazil</i>) | 1837 |
| Effects of Angiotensin, Vasopressin and Aldosterone on Proliferation of MCF-7 Cells and Their Sensitivity to Doxorubicin. J.M. DELOU, A.G. LOPES, M.A. CAPELLA (<i>Rio de Janeiro, RJ, Brazil</i>) | 1843 |
| Combinatorial Effects of PARP Inhibitor PJ34 and Histone Deacetylase Inhibitor Vorinostat on Leukemia Cell Lines. E. JASEK, M. GAJDA, G.J. LIS, M. JASIŃSKA, J.A. LITWIN (<i>Krakow, Poland</i>) | 1849 |
| Curcumin Suppresses Vasculogenic Mimicry Capacity of Hepatocellular Carcinoma Cells through STAT3 and PI3K/AKT Inhibition. K. CHIABLAEM, K. LIRDPRAPAMONGKOL, S. KEERATICHAMROEN, R. SURARIT, J. SVASTI (<i>Bangkok, Thailand</i>) | 1857 |
| Potent Reactive Oxygen Species-JNK-p38 Activation by Sodium Salicylate Potentiates Death of Primary Effusion Lymphoma Cells. K. VAETEEWOOTTACHARN, M. MITCHAI, P. SRIKOON, S. HATTORI, R. KARIYA, K. MATSUDA, S. WONGKHAM, S. OKADA (<i>Kumamoto, Japan; Khon Kaen, Thailand</i>) | 1865 |
| Impact of S100A8 Expression on Kidney Cancer Progression and Molecular Docking Studies for Kidney Cancer Therapeutics. Z. MIRZA, H.-J. SCHULTEN, H.M. FARSI, J.A. AL-MAGHRABI, M.A. GARI, A.G. CHAUDHARY, A.M. ABUZENADAH, M.H. AL-QAHTANI, S. KARIM (<i>Jeddah, Saudi Arabia</i>).... | 1873 |
| The Influence of Retinoic Acid and Thalidomide on the Radiosensitivity of U343 Glioblastoma Cells. D. MILANOVIĆ, P. MAIER, D.H. SCHANNE, F. WENZ, C. HERSKIND (<i>Mannheim; Freiburg, Germany</i>) | 1885 |
| Piperine Enhances the Efficacy of TRAIL-based Therapy for Triple-negative Breast Cancer Cells. S. ABDELHAMED, S. YOKOYAMA, A. REFAAT, K. OGURA, H. YAGITA, S. AWALE, I. SAIKI (<i>Sugitani, Toyama; Tokyo, Japan</i>) | 1893 |

| | |
|--|------|
| Anticancer Activity of Novel Pyrido[2,3- <i>b</i>]indolizine Derivatives: The Relevance of Phenolic Substituents. A. BOOT, AL. BRITO, T. VAN WEZEL, H. MORREAU, M. COSTA, F. PROENÇA (<i>Leiden, Netherlands; Braga, Portugal</i>) | 1673 |
| Uptake and Efflux of Rhenium in Cells Exposed to Rhenium Diseleno-Ether and Tissue Distribution of Rhenium and Selenium After Rhenium Diseleno-Ether Treatment in Mice. P. COLLERY, G. BASTIAN, F. SANTONI, A. MOHSEN, M. WEI, T. COLLERY, A. TOMAS, D. DESMAELE, J. D'ANGELO (<i>Algajola; Paris; Bastia; Chatenay-Malabry; Maisons Alfort, France</i>) | 1679 |
| Quercetin-3- <i>O</i> -glucoside Induces Human DNA Topoisomerase II Inhibition, Cell Cycle Arrest and Apoptosis in Hepatocellular Carcinoma Cells. S. SUDAN, H.P. VASANTHA RUPASINGHE (<i>Truro, NS, Canada</i>) | 1691 |
| Sodium Butyrate, a Histone Deacetylase Inhibitor, Regulates Lymphangiogenic Factors in Oral Cancer Cell Line HSC-3. T. YAMAMURA, N. MATSUMOTO, Y. MATSUE, M. OKUDERA, Y. NISHIKAWA, Y. ABIKO, K. KOMIYAMA (<i>Tokyo; Matsudo, Chiba, Japan</i>) | 1701 |
| Synergistic Inhibition of HCC and Liver Cancer Stem Cell Proliferation by Targeting RAS/RAF/MAPK and WNT/ β -Catenin Pathways. R. GALUPPO, E. MAYNARD, M. SHAH, M.F. DAILY, C. CHEN, B.T. SPEAR, R. GEDALY (<i>Lexington, KY, USA</i>) | 1709 |
| Enhanced Efficacy of CKD-516 in Combination with Doxorubicin: Pre-clinical Evaluation Using a Hepatocellular Carcinoma Xenograft Model. Y.I. KIM, K.W. KIM, H.K. LEE, J. PARK, J.W. CHUNG, H. YOUN, S.J. KIM, D.-H. KIM, J.-C. TSENG, J.M. LEE (<i>Seoul, Republic of Korea; Boston, MA, USA</i>) | 1715 |
| Silibinin Down-regulates Expression of Secreted Phospholipase A ₂ Enzymes in Cancer Cells. A. HAGELGANS, B. NACKE, M. ZAMARAEVA, G. SIEGERT, M. MENSCHIKOWSKI (<i>Dresden, Germany; Bialystok, Poland</i>) | 1723 |
| Endoplasmic Reticulum Stress Response as a Possible Mechanism of Cyclooxygenase-2-independent Anticancer Effect of Celecoxib. W. CHA, S.-W. PARK, T.-K. KWON, J.H. HAH, M.-W. SUNG (<i>Seoul; Pusan, Republic of Korea</i>) | 1731 |
| Multidrug Resistance Reversing Activity of Newly Developed Phenothiazines on P-glycoprotein (ABCB1)-related Resistance of Mouse T-Lymphoma Cells. G. SPENGLER, D. TAKÁCS, Á. HORVÁTH, Z. RIEDL, G. HAJÓS, L. AMARAL, J. MOLNÁR (<i>Szeged; Budapest, Hungary; Lisbon, Portugal</i>) | 1737 |
| Quantitative Structure–Activity Relationship Analysis of Cytotoxicity and Anti-UV Activity of 2-Aminotropones. S. SEKINE, C. SHIMODAIRA, Y. UESAWA, H. KAGAYA, Y. KANDA, M. ISHIHARA, O. AMANO, H. SAKAGAMI, H. WAKABAYASHI (<i>Sakado, Saitama; Kiyose, Tokyo, Japan</i>) | 1743 |
| Translymphatic Chemotherapy Targeting Sentinel Lymph Nodes Using a Novel Phospholipid Polymer–Paclitaxel Conjugate. T. OYAMA, H. TAKEUCHI, S. MATSUDA, S. OZAWA, M. KITAJIMA, Y. KITAGAWA (<i>Tokyo; Isehara; Otawara, Tochigi, Japan</i>) | 1751 |
| Dipalmitoleoyl-phosphatidylethanolamine Induces Apoptosis of NCI-H28 Malignant Mesothelioma Cells. Y. KAKU, A. TSUCHIYA, T. KANNO, T. NAKANO, T. NISHIZAKI (<i>Nishinomiya, Hyogo, Japan</i>) | 1759 |
| Metformin Suppresses Sonic Hedgehog Expression in Pancreatic Cancer Cells. M. NAKAMURA, A. OGO, M. YAMURA, Y. YAMAGUCHI, H. NAKASHIMA (<i>Kurashiki; Okayama, Japan</i>) | 1765 |
| A Novel Tetramethylnaphthalene Derivative Selectively Inhibits Adult T-Cell Leukemia (ATL) Cells <i>In Vitro</i> . M. TOYAMA, H. AOYAMA, R. MUKAI, M. NAKAMURA, K. YOSHIMURA, M. OKAMOTO, T. OHSHIMA, Y. HASHIMOTO, M. BABA (<i>Kagoshima; Tokyo; Sanuki, Kagawa, Japan</i>) | 1771 |

| | |
|---|------|
| Effective Targeting of the Epidermal Growth Factor Receptor (EGFR) for Treating Oral Cancer: A Promising Approach. F.A. RIBEIRO, J. NOGUTI, C.T. OSHIMA, D.A. RIBEIRO (<i>Santos, SP, Brazil</i>) | 1547 |
| Malignant Ascites in Ovarian Cancer and the Role of Targeted Therapeutics. E. SMOLLE, V. TAUCHER, J. HAYBAECK (<i>Graz, Austria</i>) | 1553 |
| New Possibilities in Hepatocellular Carcinoma Treatment. M. RASOOL, S. RASHID, M. AROOJ, S.A. ANSARI, K.M. KHAN, A. MALIK, M.I. NASEER, S. ZAHID, A. MANAN, M. ASIF, Z. RAZZAQ, S. ASHRAF, M.H. QAZI, Z. IQBAL, S.H. GAN, M.A. KAMAL, I.A. SHEIKH (<i>Jeddah; Riyadh, Saudi Arabia; Lahore; Quetta, Pakistan; Kelantan, Malaysia</i>) | 1563 |
| New Anticancer Agents: Role of Clinical Pharmacy Services. D. LEVEQUE, A. DELPEUCH, B. GOURIEUX (<i>Strasbourg, France</i>) | 1573 |
| Subcutaneous Administration of Anticancer Agents. D. LEVEQUE (<i>Strasbourg, France</i>) | 1579 |
| New Treatment Paradigm for Patients with Anaplastic Oligodendroglial Tumors. J. POLIVKA JR., J. POLIVKA, V. ROHAN, O. TOPOLCAN (<i>Plzen, Czech Republic</i>) | 1587 |
| Targeting Tropomyosin-receptor Kinase Fused Gene in Cancer. Y. CHEN, S.-H. TSENG (<i>New Taipei; Taoyuan; Taipei, Taiwan, ROC</i>) | 1595 |
| <i>Experimental Studies</i> | |
| Cytotoxic Activity of <i>N, N'</i> -Bis (2-hydroxybenzyl) ethylenediamine Derivatives in Human Cancer Cell Lines. M.A. MUSA, V.L.D. BADISA, L.M. LATINWO (<i>Tallahassee, FL, USA</i>) | 1601 |
| The Addition of a Pregnenolone Pendant Group Enhances the Anticancer Properties of Titanocene Dichloride in a MCF-7 Xenograft Model. G. RAMOS, Y. LOPERENA, G. ORTIZ, F. REYES, A. SZETO, J. VERA, J. VELEZ, J. MORALES, D. MORRERO, L. CASTILLO, S. DHARMAWARDHANE, E. MELENDEZ, A.V. WASHINGTON (<i>Bayamón; Mayagüez; San Juan, PR, USA</i>) | 1609 |
| Ascorbic Acid Induces either Differentiation or Apoptosis in MG-63 Osteosarcoma Lineage. M.T. VALENTI, M. ZANATTA, L. DONATELLI, G. VIVIANO, C. CAVALLINI, M.T. SCUPOLI, L.D. CARBONARE (<i>Verona, Italy</i>) | 1617 |
| Bosutinib Reduces the Efficacy of Dasatinib in Triple-negative Breast Cancer Cell Lines. M. TARPLEY, T.T. ABDISSA, G.L. JOHNSON, J.E. SCOTT (<i>Durham; Chapel Hill, NC, USA</i>) | 1629 |
| Specific RSK Kinase Inhibition by Dibenzyl Trisulfide and Implication for Therapeutic Treatment of Cancer. H.I.C. LOWE, C.O.B. FACEY, N.J. TOYANG, J.L. BRYANT (<i>Kingston, Jamaica, West Indies; Wellington, FL; Baltimore, MD, USA</i>) | 1637 |
| Mechanisms by which Synthetic 6,7-Annulated-4-substituted Indole Compounds with Anti-proliferative Activity Disrupt Mitosis and Block Cytokinesis in Human HL-60 Tumor Cells <i>In Vitro</i> . J.-P.H. PERCHELLET, E.M. PERCHELLET, C.R. SINGH, M.T. MONNETT, E.R. STUDER, P.D. THORNTON, N. BROWN, D. HILL, B. NEUENSWANDER, G.H. LUSHINGTON, C. SANTINI, K.R. BUSZEK (<i>Manhattan; Lawrence, KS; Kansas City, MO, USA</i>) | 1643 |
| Cytarabine-resistant Leukemia Cells Are Moderately Sensitive to Clofarabine <i>In Vitro</i> . T. YAMAUCHI, K. UZUI, R. NISHI, H. SHIGEMI, T. UEDA (<i>Eiheiji, Fukui, Japan</i>) | 1657 |
| Inhibitory Effect of Orally-administered Sulfated Polysaccharide Ascophyllan Isolated from <i>Ascophyllum nodosum</i> on the Growth of Sarcoma-180 Solid Tumor in Mice. Z. JIANG, R. ABU, S. ISAKA, S. NAKAZONO, M. UENO, T. OKIMURA, K. YAMAGUCHI, T. ODA (<i>Nagasaki, Japan; Shimonoseki, Yamaguchi, Japan</i>) | 1663 |